|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
HU230048B1
(hu)
|
1996-02-09 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazása
|
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
|
PL218992B1
(pl)
*
|
2002-07-19 |
2015-02-27 |
Abbott Biotech Ltd |
Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
|
|
PT1948235E
(pt)
|
2005-11-01 |
2013-11-26 |
Abbvie Biotechnology Ltd |
Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
|
|
EP2738179A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
WO2007120656A2
(en)
*
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9605064B2
(en)
*
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
TWI498137B
(zh)
|
2006-06-30 |
2015-09-01 |
Abbvie Biotechnology Ltd |
自動注射裝置
|
|
NZ613356A
(en)
|
2006-10-27 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Crystalline anti-htnfalpha antibodies
|
|
FR2909643B1
(fr)
*
|
2006-12-11 |
2011-03-04 |
Valois Sas |
Dispositif de distribution de produit fluide
|
|
US8092998B2
(en)
*
|
2007-05-31 |
2012-01-10 |
Abbott Laboratories |
Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
|
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
|
WO2009020654A1
(en)
|
2007-08-08 |
2009-02-12 |
Abbott Laboratories |
Compositions and methods for crystallizing antibodies
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
KR20210049186A
(ko)
|
2007-11-30 |
2021-05-04 |
애브비 바이오테크놀로지 리미티드 |
단백질 제형 및 이의 제조방법
|
|
ES2394589T3
(es)
|
2007-12-14 |
2013-02-04 |
Aerodesigns, Inc |
Suministro de productos alimenticios transformables en aerosol
|
|
CA2710333A1
(en)
*
|
2008-01-03 |
2009-07-09 |
Abbott Biotechnology Ltd. |
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
|
EP2249809A1
(en)
|
2008-01-15 |
2010-11-17 |
Abbott GmbH & Co. KG |
Powdered protein compositions and methods of making same
|
|
EP2303291B1
(en)
*
|
2008-05-23 |
2013-02-27 |
The Lauridsen Group, Inc. |
Iga and igg for reducing lung inflammation in an animal
|
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
|
NZ595694A
(en)
*
|
2009-05-04 |
2013-09-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
US8758301B2
(en)
|
2009-12-15 |
2014-06-24 |
Abbvie Biotechnology Ltd |
Firing button for automatic injection device
|
|
US7985733B1
(en)
|
2010-01-06 |
2011-07-26 |
The Medicines Company |
Buffer-based method for preparing bivalirudin drug product
|
|
GB201005064D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
JP6022441B2
(ja)
|
2010-04-30 |
2016-11-09 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗Ｃ５ａ抗体およびその抗体の使用のための方法
|
|
CA2801917C
(en)
|
2010-06-03 |
2017-04-25 |
Abbvie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
CN103458926B
(zh)
|
2010-11-11 |
2016-10-26 |
艾伯维生物技术有限公司 |
改进的高浓度抗TNF α 抗体液体制剂
|
|
RU2602039C2
(ru)
|
2011-01-24 |
2016-11-10 |
Эббви Байотекнолоджи Лтд. |
Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
ES2959198T3
(es)
*
|
2012-07-24 |
2024-02-21 |
Avalyn Pharma Inc |
Compuestos análogos de pirfenidona y piridona en aerosol
|
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
US10058530B2
(en)
|
2012-10-25 |
2018-08-28 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
|
US9855276B2
(en)
|
2012-10-25 |
2018-01-02 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
EP3473272A1
(en)
|
2013-03-29 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
|
CN105473133A
(zh)
|
2013-04-30 |
2016-04-06 |
欧缇托匹克公司 |
干粉制剂及使用方法
|
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
|
WO2015002703A1
(en)
*
|
2013-05-23 |
2015-01-08 |
Aztherapies, Inc |
Methods for delivering cromolyn
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
AU2014340182B2
(en)
|
2013-10-22 |
2019-05-23 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
AU2015307868B2
(en)
*
|
2014-08-26 |
2020-08-27 |
Amgen K-A, Inc. |
Method for treating psoriasis patient which received anti-TNF-alpha antibody therapy
|
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
EP3506894B1
(en)
|
2016-08-31 |
2023-08-23 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
|
SG11202000105QA
(en)
|
2017-07-14 |
2020-02-27 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies and uses thereof
|
|
WO2019017995A1
(en)
|
2017-07-20 |
2019-01-24 |
Aztherapies, Inc. |
FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
|
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
|
EP3684338A4
(en)
|
2017-09-22 |
2021-06-23 |
Otitopic Inc. |
DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
|
|
EP3700928A1
(en)
|
2017-10-26 |
2020-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
|
|
KR20250174998A
(ko)
*
|
2018-03-08 |
2025-12-15 |
어플라이드 몰레큘라 트랜스포트 인크. |
경구 전달용 독소-유래 전달 구조체
|
|
WO2019178516A1
(en)
*
|
2018-03-16 |
2019-09-19 |
SEN-JAM Pharmaceutical LLC |
Methods and compositions to treat enteropathic arthritis
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
|
|
EP3814373A1
(en)
|
2018-06-28 |
2021-05-05 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
JP2021529771A
(ja)
|
2018-07-02 |
2021-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
クロモリンナトリウムおよびα−ラクトースの粉末製剤
|
|
MX2021004994A
(es)
|
2018-10-30 |
2021-06-15 |
Alexion Pharma Inc |
Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
|
|
US12383528B2
(en)
|
2018-12-10 |
2025-08-12 |
The General Hospital Corporation |
Cromolyn esters and uses thereof
|
|
US11793834B2
(en)
|
2018-12-12 |
2023-10-24 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
JP2023520580A
(ja)
|
2020-04-06 |
2023-05-17 |
ザ ジェネラル ホスピタル コーポレイション |
コロナウイルス誘発炎症状態の処置方法
|
|
BR112022021450A2
(pt)
|
2020-04-24 |
2022-12-27 |
Millennium Pharm Inc |
O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
|
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|
|
WO2022146914A1
(en)
|
2020-12-28 |
2022-07-07 |
The General Hospital Corporation |
Cromolyn derivatives and uses thereof
|
|
EP4320149A1
(en)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Antibodies targeting complement factor d and uses therof
|
|
IL307939A
(en)
|
2021-04-26 |
2023-12-01 |
Millennium Pharm Inc |
Anti-CLEC12A antibodies and uses thereof
|
|
PE20242205A1
(es)
|
2021-04-26 |
2024-11-19 |
Millennium Pharm Inc |
Anticuerpos anti-adgre2 y usos de los mismos
|
|
PE20242001A1
(es)
|
2021-10-20 |
2024-09-27 |
Takeda Pharmaceuticals Co |
Composiciones que actuan sobre bcma y metodos de uso de estas
|
|
CN116763763B
(zh)
*
|
2022-12-05 |
2024-08-30 |
齐鲁制药有限公司 |
一种司美格鲁肽吸入喷雾剂及其制备方法
|